
STEP UP: Higher Semaglutide Doses Yield Greater Weight Loss in Obesity
Use of semaglutide 7.2 mg (Wegovy) was associated with a mean reduction in body weight of 21% in people with obesity, according to results of the STEP UP trial. Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA 2025), …